94 related articles for article (PubMed ID: 26116990)
1. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™.
Sun F; Lee L; Zhang Z; Wang X; Yu Q; Duan X; Chan E
Eur J Pharm Sci; 2015 Sep; 77():290-302. PubMed ID: 26116990
[TBL] [Abstract][Full Text] [Related]
2. Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.
Sun F; Li J; Yu Q; Chan E
Eur J Pharm Biopharm; 2012 Feb; 80(2):323-31. PubMed ID: 22061261
[TBL] [Abstract][Full Text] [Related]
3. Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection.
Sun F; Ong JC; Yu Q; Chan E
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(3-4):285-90. PubMed ID: 21195038
[TBL] [Abstract][Full Text] [Related]
4. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
[TBL] [Abstract][Full Text] [Related]
6. 3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.
Tam EK; Nguyen TM; Lim CZ; Lee PL; Li Z; Jiang X; Santhanakrishnan S; Tan TW; Goh YL; Wong SY; Yang H; Ong EH; Hill J; Yu Q; Chai CL
ChemMedChem; 2015 Jan; 10(1):173-82. PubMed ID: 25319940
[TBL] [Abstract][Full Text] [Related]
7. Cell-based proteome profiling using an affinity-based probe (AfBP) derived from 3-deazaneplanocin A (DzNep).
Tam EK; Li Z; Goh YL; Cheng X; Wong SY; Santhanakrishnan S; Chai CL; Yao SQ
Chem Asian J; 2013 Aug; 8(8):1818-28. PubMed ID: 23749335
[TBL] [Abstract][Full Text] [Related]
8. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
10. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
11. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).
Jiang X; Lim CZ; Li Z; Lee PL; Yatim SM; Guan P; Li J; Zhou J; Pan J; Chng WJ; Chai CL; Yu Q
PLoS One; 2015; 10(4):e0122983. PubMed ID: 25928216
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
15. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
[TBL] [Abstract][Full Text] [Related]
16. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
Gao ZW; Zhu YT; Yu MM; Zan B; Liu J; Zhang YF; Chen XY; Li XN; Zhong DF
Acta Pharmacol Sin; 2015 Dec; 36(12):1528-36. PubMed ID: 26592518
[TBL] [Abstract][Full Text] [Related]
18. [Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
Yu MM; Gao ZW; Chen XY; Zhong DF
Yao Xue Xue Bao; 2014 Dec; 49(12):1684-8. PubMed ID: 25920197
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.
Bradshaw-Pierce EL; Eckhardt SG; Gustafson DL
Clin Cancer Res; 2007 May; 13(9):2768-76. PubMed ID: 17473210
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.
Shirota K; Kaneko M; Sasaki M; Minato K; Fujikata A; Ohta S; Hisaka A; Suzuki H
Drug Metab Dispos; 2015 Feb; 43(2):217-26. PubMed ID: 25422274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
